Icon Advisers Inc. Co. Raises Stock Position in The Chemours Company (NYSE:CC)

Icon Advisers Inc. Co. lifted its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 10.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 436,365 shares of the specialty chemicals company's stock after buying an additional 42,300 shares during the period. Chemours comprises about 1.7% of Icon Advisers Inc. Co.'s holdings, making the stock its 5th largest position. Icon Advisers Inc. Co. owned approximately 0.29% of Chemours worth $7,375,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC boosted its position in Chemours by 99.7% in the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after purchasing an additional 765 shares during the last quarter. Quadrant Capital Group LLC grew its position in Chemours by 100.4% during the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after buying an additional 1,119 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in Chemours during the fourth quarter worth about $48,000. KBC Group NV raised its position in Chemours by 38.2% in the fourth quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after acquiring an additional 1,708 shares during the period. Finally, Sterling Capital Management LLC boosted its stake in Chemours by 54.8% in the fourth quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock valued at $143,000 after acquiring an additional 2,991 shares during the last quarter. Institutional investors own 76.26% of the company's stock.

Chemours Price Performance

NYSE CC traded up $0.35 during trading hours on Friday, hitting $11.37. The company had a trading volume of 1,640,388 shares, compared to its average volume of 1,834,480. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of 19.94 and a beta of 1.84. The Chemours Company has a 52 week low of $9.33 and a 52 week high of $29.21. The firm has a 50 day simple moving average of $13.83 and a 200 day simple moving average of $17.33.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.10 by $0.01. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.36 billion during the quarter, compared to analysts' expectations of $1.37 billion. Equities research analysts expect that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were given a $0.25 dividend. The ex-dividend date was Friday, February 28th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 8.80%. Chemours's dividend payout ratio (DPR) is presently 175.44%.

Wall Street Analysts Forecast Growth

CC has been the topic of a number of research reports. The Goldman Sachs Group lowered their price target on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. BMO Capital Markets decreased their target price on Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research report on Wednesday, February 19th. Barclays dropped their price target on Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 1st. Mizuho set a $15.00 price objective on Chemours in a report on Tuesday. Finally, Morgan Stanley dropped their price objective on shares of Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $21.56.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.